Trial Profile
A phase III long-term study to evaluate the safety and efficacy of TAC-202 in patients with perennial or seasonal allergic rhinitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Bilastine (Primary)
- Indications Perennial allergic rhinitis; Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 07 Dec 2015 Status changed from active, no longer recruiting to completed.
- 13 Aug 2015 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2015 Status changed from not yet recruiting to recruiting.